• LY2603618: Chk1 Inhibitor Workflows for DNA Damage Research

  2026-05-02

  LY2603618 is a potent, highly selective Chk1 inhibitor that enables precise modulation of DNA damage response and cell cycle arrest at the G2/M phase. This guide delivers actionable protocols, troubleshooting strategies, and experimental insights for leveraging LY2603618 in cancer research, with a spotlight on synergy in non-small cell lung cancer models.

• SM-164: Bivalent Smac Mimetic for Precision Apoptosis Induct

  2026-05-02

  SM-164 empowers cancer researchers with rapid, tunable apoptosis induction by targeting IAPs, enabling high-sensitivity, reproducible results in both cell-based and in vivo models. This guide translates recent advances in signalosome assembly and mechanistic insights into actionable experimental workflows and troubleshooting tips for maximizing your outcomes.

• Aumolertinib Plus Radiation in EGFR-Mutant NSCLC Brain Metas

  2026-05-01

  This study systematically evaluated the therapeutic benefit of combining the third-generation EGFR-TKI aumolertinib with ionizing radiation in models of EGFR-mutant non-small cell lung cancer (NSCLC) brain metastases. The work offers new mechanistic and preclinical evidence supporting the synergy of this combination, with implications for overcoming therapeutic barriers in brain metastasis management.

• GluN2A/2B Modulate Connexins in Orofacial Allodynia via MAPK

  2026-04-30

  This study unveils how NMDA receptor subunits GluN2A and GluN2B differentially regulate connexin and pannexin expression in the trigeminal ganglion, contributing to orofacial inflammatory allodynia during TMJ inflammation. By dissecting intracellular signaling, it reveals distinct roles for these subunits in peripheral sensitization, offering new directions for targeted pain interventions.

• Glabridin-Gold(I) Complex Enhances Antitumor Immunity via Tr

  2026-04-30

  A novel glabridin-gold(I) complex (6d) was developed to target both thioredoxin reductase (TrxR) and MAPK signaling, achieving dual immunomodulation in liver cancer models. The study demonstrates that 6d synergistically enhances dendritic cell maturation, reduces immunosuppressive cell populations, and modulates PD-L1/GzmB expression, indicating potential for improved cancer immunotherapy outcomes.

• LY2109761: Strategic TGF-β Pathway Modulation for Translatio

  2026-04-29

  Explore how LY2109761, a dual TGF-β receptor kinase inhibitor, empowers translational researchers to dissect and therapeutically modulate the invasion-proliferation axis in glioblastoma and pancreatic cancer, with unique mechanistic insights drawn from recent advances in post-translational regulation and radiosensitization.

• Ornithine-ZBTB7A Axis in Realgar-Induced CNS Toxicity: New I

  2026-04-29

  This study uncovers how realgar-derived arsenic disrupts both hepatic ornithine metabolism and astrocyte glycolysis via the OTC-ornithine-ZBTB7A pathway, leading to central nervous system toxicity. The findings highlight mechanistic links between liver dysfunction and neurotoxicity, offering new experimental frameworks for metabolic and CNS toxicity research.

• Porous Graphene LDI-MSI Reveals Brain Lipid Asymmetry Post-E

  2026-04-28

  This study introduces a porous laser-induced graphene (LIG) substrate for matrix-free laser desorption/ionization mass spectrometry imaging (LDI-MSI), enabling unprecedented 3 μm spatial resolution and streamlined workflows. Application of this platform uncovers dynamic, lateralized lipid metabolism in mouse brains following acute ethanol intoxication, offering new insights into spatially resolved metabolic responses.

• Jiedu Xiaozheng Yin Drives M1 Macrophage Polarization in CAC

  2026-04-28

  Liu et al. demonstrate that Jiedu Xiaozheng Yin (JXY), a traditional Chinese medicine compound, inhibits the progression of colitis-associated colorectal cancer (CAC) by shifting macrophage polarization toward the M1 phenotype through TLR4 pathway activation. This mechanistic insight highlights the therapeutic potential of targeting macrophage plasticity in the tumor microenvironment for CAC management.

• Gamithromycin (BA1074): Tissue Distribution and PK/PD Insigh

  2026-04-27

  Explore the unique tissue distribution and advanced pharmacokinetic/pharmacodynamic (PK/PD) properties of Gamithromycin (BA1074) in veterinary research. This article reveals new, evidence-backed considerations for respiratory infection models, setting it apart from standard mechanism or protocol guides.

• Simvastatin (Zocor): Mechanistic Evidence and Experimental U

  2026-04-27

  Simvastatin (Zocor) is a potent HMG-CoA reductase inhibitor used in hyperlipidemia and cancer research. Its lactone prodrug form is hydrolyzed in vivo to an active β-hydroxyacid that suppresses cholesterol biosynthesis and modulates cell cycle regulators. This article details its biological rationale, mechanism, application boundaries, and protocol parameters for robust experimental design.

• SARS-CoV-2 N Protein Disrupts GADD34-Mediated Antiviral Immu

  2026-04-26

  This study reveals a novel mechanism by which the SARS-CoV-2 nucleocapsid protein antagonizes the GADD34-mediated innate immune pathway. By sequestering GADD34 mRNA into atypical stress granule-like foci, the viral N protein impairs IRF3 nuclear translocation and dampens interferon responses, highlighting new targets for antiviral research.

• Sabutoclax: Pan-Bcl-2 Inhibitor Transforming Apoptosis Assay

  2026-04-25

  Sabutoclax sets a new standard for apoptosis induction in cancer research with its multi-targeted inhibition and exceptional cell permeability. Learn how to harness its unique properties for streamlined experimental workflows, robust in vitro and in vivo modeling, and reliable troubleshooting.

• Trametinib (GSK1120212): Optimizing MEK-ERK Pathway Inhibiti

  2026-04-24

  Trametinib (GSK1120212) delivers precise, ATP-noncompetitive MEK1/2 inhibition for advanced oncology and vascular research. With subnanomolar potency and proven cell cycle and apoptosis effects, it empowers experimental control in both standard and emerging disease models.

• Necrostatin 2 (Nec-2): Potent RIPK2 Inhibition in Necroptosi

  2026-04-24

  Necrostatin 2 (Nec-2) is a high-affinity, selective inhibitor of RIPK2 kinase, enabling precise necroptosis inhibition in disease models. This article details its mechanism, benchmark data, and best practices for application in programmed necrotic cell death research.

413 records 17/28 page Previous Next First page 上5页 1617181920 下5页 Last page